What Happened
Vanda Pharmaceuticals reported positive topline results Tuesday from Study 3601 (VP-VLY-686-3601), a randomized, placebo-controlled Phase 3 trial of NEREUS (tradipitant), an oral neurokinin-1 receptor antagonist given to prevent vomiting triggered by GLP-1 receptor agonist therapy.
The test condition was deliberately harsh. All 306 participants received a single 1 mg dose of semaglutide with no gradual titration — highly emetogenic precisely because it skips the ramp that normally protects patients starting the drug. Participants were randomized 142 to tradipitant and 164 to placebo.
Any vomiting occurred in 43.0% (61/142) of tradipitant-treated participants versus 58.5% (96/164) on placebo (p=.006, site-adjusted) — a 27% relative reduction, an absolute difference of 15.5 percentage points. The key secondary endpoint, vomiting combined with a worst nausea score of 3 or higher on a 0–5 scale, came in at 33.1% versus 50.6% (p=.002), a 35% relative reduction.
Post hoc analyses found the widest gaps in the heaviest outcomes: frequent multiday vomiting (>2 episodes on more than one day) fell to 6.3% from 15.9% (p=.008, a 60% relative reduction), and extreme vomiting (>10 total episodes) to 2.8% from 14.6% (p=.0003, an 81% reduction). Vanda labeled both exploratory rather than confirmatory. Safety was consistent with earlier studies, with no new signals.
Who Is Affected
In practical terms, the entire GLP-1 class. Vanda says the mechanism — blocking substance P signaling in the area postrema and nucleus tractus solitarius, two central emetic relay points — sits upstream of the differences between receptor agonists, so the company expects it to work across the class and across formulations.
The clinical logic is retention, not comfort. A retrospective cohort of 125,474 U.S. adults with overweight or obesity found 53.6% discontinued GLP-1 therapy within one year, with gastrointestinal adverse events among the factors associated with stopping. An antiemetic that lets a patient hold a dose protects the benefit the regimen was prescribed for.
Tradipitant is not an experimental molecule. The FDA approved it in December 2025 for prevention of motion-induced vomiting. This would be a supplemental NDA — an added indication for a drug already on the market.
Timeline
- November 2025 — Phase 2 readout: 29.3% versus 58.6% vomiting (p=.0016), a 50% relative reduction.
- May 2026 — Vanda opens the confirmatory program.
- October 27, 2026 — Phase 3 Study 3601 topline; primary and key secondary endpoints met.
- 2027 — planned FDA meeting ahead of a supplemental NDA submission.
What This Means for Researchers
Tolerability is now a development target in its own right, not a footnote on weight-loss trials; expect adjunct-therapy arms in future obesity and diabetes protocols. The shape of the response matters as much as its size — modest on any vomiting, large on multi-day and extreme vomiting, which is what a centrally acting antiemetic should produce. The post hoc numbers remain post hoc: an 81% reduction in extreme vomiting is a hypothesis worth testing prospectively, not a settled effect.
How to Verify Your Peptides
Better tolerability data does not make unverified vials safer. Three references cover the measurements: how testing works, HPLC versus LC-MS, and what identity, purity and fill-weight results each actually establish.
Safe Alternatives
Gastrointestinal side effects should go to the prescriber before anything changes — titration pace and antiemetic choice are clinical decisions. For reference, see the semaglutide and tirzepatide compound overviews, browse peptide references, or compare published vendor profiles where independent testing is documented.
Sources
Company disclosures and regulatory announcements; cohort data on GLP-1 persistence; industry reports.